While the exact mechanisms by which pks+ E. coli modulates the TIME remain unclear, this represents a promising avenue for future research, potentially uncovering novel therapeutic targets and strategies to enhance anti-tumor immunity. This evidence concerns the gene ARAF and neoplasm.